Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00301106 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver
A Phase 1 study, sponsored by Max Sung.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00301106: Clinical Trial Phase 1 study, sponsored by Max Sung.
NCT00301106 is a Phase 1 study that was terminated before completion, run by Max Sung. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00301106, a Phase 1 study, was terminated before completion, sponsored by Max Sung.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapy using a gene-modified virus that can make interleukin-12 may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of a gene-modified virus that can make interleukin-12 in treating women with breast cancer that has spread to the liver.
Primary Outcome
Serial monitoring of tumor necrosis factor alpha (TNFα) levels
Interventions
- BIOLOGICAL adenovirus-mediated human interleukin-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Why NCT00301106 stopped before completion
NCT00301106 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which adenovirus-mediated human interleukin-12 is the first listed.
NCT00301106 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00301106 about?
NCT00301106 is a clinical study titled "Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver". RATIONALE: Biological therapy using a gene-modified virus that can make interleukin-12 may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of a gene-modified virus that can make interleukin-12 in treating w...
What is the current status of trial NCT00301106?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2005-10. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00301106?
The interventions under investigation include: adenovirus-mediated human interleukin-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00301106?
This trial is sponsored by Max Sung, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00301106's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia